文献速递泌尿生殖MRUS

主动监测前列腺癌患者中前列腺MRI与经直肠前列腺穿刺活检的暂时性健康影响

Temporary Health Impact of Prostate MRI and Transrectal Prostate Biopsy in Active Surveillance Prostate Cancer Patients.
PubMed 文献 · J Am Coll Radiol · 2019-02-04

前瞻性观察性患者报告结局研究纳入122例Gleason 6主动监测前列腺癌患者,比较前列腺mpMRI与经直肠穿刺活检后24-72小时的暂时性健康影响;经直肠穿刺活检的测试相关生活质量评分显著低于mpMRI(0.82 vs 0.95,P<.001),以术中疼痛域差异最大。

要点

  • 经直肠前列腺穿刺活检后24-72小时测试相关生活质量评分为0.82,低于mpMRI的0.95(P<.001)。
  • 两组差异最大的域为术中疼痛,经直肠活检均值2.6,mpMRI均值1.3(P<.001)。
  • TMI评分范围0(死亡)至1(完全健康),各域评分1(无健康影响)至5(极度健康影响)。

核心结论

  • 经直肠前列腺穿刺活检的暂时性健康影响大于前列腺mpMRI,表现为测试相关生活质量评分更低(0.82 vs 0.95,P<.001)。

研究设计与样本

  • 前瞻性观察性患者报告结局研究,经机构审查委员会批准并符合HIPAA,2017年11月至2018年7月开展。
  • 纳入Gleason 6主动监测前列腺癌男性,接受前列腺mpMRI或经直肠前列腺穿刺活检。
  • 共招募122例,90%(110/122;MRI 55/60,活检55/62)在检查后24至72小时通过电话完成问卷。
  • 主要结局为测试相关生活质量汇总效用评分,来自测试疾病指数(TMI),量表0=死亡、1=完全健康。
  • TMI分为7个域,每域评分1(无健康影响)至5(极度健康影响);两组比较采用Mann-Whitney U检验。

诊断标准与关键数值

  • TMI汇总效用评分量表:0=死亡,1=完全健康;域评分:1=无健康影响,5=极度健康影响。
  • 经直肠活检测试相关生活质量评分0.82(95%CI 0.79-0.85)vs mpMRI 0.95(95%CI 0.94-0.97),P<.001。
  • 术中疼痛域均值:经直肠活检2.6(95%CI 2.4-2.8)vs mpMRI 1.3(95%CI 1.1-1.5),P<.001,为最大域水平差异。

临床应用与阅片要点

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

PURPOSE: To assess the temporary health impact of prostate multiparametric MRI (mpMRI) and transrectal prostate biopsy in an active surveillance prostate cancer population.

METHODS: A two-arm institutional review board-approved HIPAA-compliant prospective observational patient-reported outcomes study was performed from November 2017 to July 2018. Inclusion criteria were men with Gleason 6 prostate cancer in active surveillance undergoing either prostate mpMRI or transrectal prostate biopsy. A survey instrument was constructed using validated metrics in consultation with the local patient- and family-centered care organization. Study subjects were recruited at the time of diagnostic testing and completed the instrument by phone 24 to 72 hours after testing. The primary outcome measure was summary testing-related quality of life (summary utility score), derived from the testing morbidities index (TMI) (scale: 0 = death and 1 = perfect health). TMI is stratified into seven domains, with each domain scored from 1 (no health impact) to 5 (extreme health impact). Testing-related quality-of-life measures in the two cohorts were compared with Mann-Whitney U test.

RESULTS: In all, 122 subjects were recruited, and 90% (110 of 122 [MRI 55 of 60, biopsy 55 of 62]) successfully completed the survey instrument. The temporary quality-of-life impact of transrectal biopsy was significantly greater than that of prostate mpMRI (0.82, 95% confidence interval [CI] 0.79-0.85, versus 0.95, 95% CI 0.94-0.97; P < .001). The largest mean domain-level difference was for intraprocedural pain (transrectal biopsy 2.6, 95% CI 2.4-2.8, versus mpMRI 1.3, 95% CI 1.1-1.5; P < .001).

CONCLUSION: Transrectal prostate biopsy has greater temporary health impact (lower testing-related quality-of-life measure) than prostate mpMRI.

来源:J Am Coll Radiol,查看原文。版权归原作者所有。

引用

  1. Shankar PR, Maturen KE, George AK, et al. Temporary Health Impact of Prostate MRI and Transrectal Prostate Biopsy in Active Surveillance Prostate Cancer Patients. J Am Coll Radiol. 2019. PMID: 30733160. doi:10.1016/j.jacr.2018.11.031

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。